Adcetris brentuximab vedotin: Interim Phase I data
Interim data from an open-label, dose-escalation, North American Phase I trial in 44 patients with newly diagnosed Hodgkin's lymphoma showed that Adcetris plus ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) chemotherapy (n=25) led to complete remission in all 15 patients who completed treatment. Of the remaining 10 patients, 5 withdrew from the study and 5 are still receiving treatment. However, 10 patients receiving Adcetris plus ABVD chemotherapy had an event of pulmonary toxicity compared to 0 patients receiving Adcetris plus AVD (adriamycin, vinblastine and dacarbazine) chemotherapy (n=19). As a result, Seattle Genetics said it does not recommend concomitant use of Adcetris with bleomycin and patients are no longer being treated in the ABVD cohorts. Response data for patients receiving Adcetris plus AVD chemotherapy are not yet available. The trial has completed enrollment of 51 patients. Data were presented at the American Society of Hematology meeting in San Diego. ...